A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
The purpose of this study is to test any good and bad effects of the study drug called pembrolizumab when it is given in combination with Y90 (TheraSphere?).
The purpose of this study is to evaluate the efficacy as well as the safety of combining pembrolizumab with Yttrium-90 radioembolization in subjects with poor prognosis hepatocellular carcinoma not eligible for liver transplant or surgical resection with well compensated liver function.
- IRB Number: 1706864763 (GI15-225)
- Research Study Identifier: TX8124
- Principal Investigator: Paul Helft, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required